Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
3M manages its wounds with Acelity buy
Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
Vistagen tries not to get depressed despite bad omens
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Looking back at April’s data digging and analysis
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
If you want blockbuster sales, buy them in
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Splitting the difference on promising pipeline asset predictions
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Boston and Coloplast sink on mesh mess
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.